Completing Funding Round, New Oncology Plans to Develop Liquid Biopsy Sequencing Test | GenomeWeb

NEW YORK (GenomeWeb) – German MDx firm New Oncology is planning to launch a liquid biopsy cancer mutation test this year supported by an undisclosed amount raised in a funding round this week.

An offshoot of German contract research and analytics firm Blackfield, New Oncology currently offers a targeted sequencing assay called NeoPlus, which profiles more than 70 cancer-associated genes for point mutations, gene amplifications, gene fusions, and other rearrangements using a target amplification and sequencing strategy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.